Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Judith Tolhurst

Psychiatry Greenwood, SC Medical Doctor

NPI 1083766711 CMS profile 906419

1547 Parkway, Suite 100, Greenwood, SC 29646

Open in the dashboard

General payments

$2,444

160 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Judith Tolhurst of Greenwood, SC is reported in the CMS Open Payments database as having received $2,444 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51 3
2024 General $25 1
2023 General $58 3
2022 General $254 11
2021 General $916 71
2020 General $470 41
2019 General $670 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judith Tolhurst
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Judith Tolhurst were reported at $51. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Judith Tolhurst Psychiatry median Middle half National median
2019 $670 $184 $59–$605 $163
2020 $470 $119 $36–$372 $114
2021 $916 $143 $43–$576 $132
2022 $254 $153 $50–$590 $149
2023 $58 $170 $56–$651 $160
2024 $25 $179 $57–$673 $164
2025 $51 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $504 17 payments
  2. Janssen Pharmaceuticals, Inc $446 22 payments
  3. Neurocrine Biosciences, Inc. $360 25 payments
  4. AbbVie, Inc. $247 31 payments
  5. Sunovion Pharmaceuticals Inc. $200 9 payments
  6. Allergan Inc. $152 22 payments
  7. Otsuka America Pharmaceutical, Inc. $144 9 payments
  8. Lundbeck LLC $127 7 payments
  9. ITI, Inc. $113 7 payments
  10. Teva Pharmaceuticals USA, Inc. $102 7 payments
  11. Other $49 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,444 160 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $446 22 payments
  2. ARISTADA Cns $415 16 payments
  3. ARISTADA Cns $415 16 payments
  4. ARISTADA INITIO $391 15 payments
  5. ARISTADA Cns $384 14 payments
  6. ARISTADA Cns $384 14 payments
  7. INVEGA TRINZA $250 9 payments
  8. VRAYLAR Neuroscience $230 30 payments
  9. LATUDA $200 9 payments
  10. VRAYLAR Neuroscience $168 23 payments
  11. Other $1,369 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,704

Median for Psychiatry: 574

Drug cost

$631,771

Median for Psychiatry: $27,624

Branded share of claims

21.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 16 $170,185
Invega Trinza Paliperidone Palmitate Brand 17 $152,759
Invega Sustenna Paliperidone Palmitate Brand 25 $90,913
Abilify Maintena Aripiprazole Brand 28 $75,077
Vraylar Cariprazine Hcl Brand 39 $53,979
Rexulti Brexpiprazole Brand 12 $17,756
Caplyta Lumateperone Tosylate Brand 11 $17,186
Lurasidone Hcl Generic 24 $13,779
Aripiprazole Generic 75 $7,777
Fluphenazine Decanoate Generic 39 $4,299

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$9,188

Medicare's payments for the services billed

Medicare patients

64

Average age 55

Services billed

153

36 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Depression 44%
Diabetes 31%
Arthritis 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ARISTADA
  • Alkermes, Inc. $20
$20 — —
LYBALVI
  • Alkermes, Inc. $5
$5 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record